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Modeling a methylmalonic acid–derived change point for serum vitamin
B-12 for adults in NHANES
Abstract
Background: No consensus exists about which cutoff point should be applied for serum vitamin B-12 (SB-12)
concentrations to define vitamin B-12 status in population-based research. Objective: The study’s aim was to
identify whether a change point exists at which the relation between plasma methylmalonic acid (MMA) and
SB-12 changes slope to differentiate between inadequate and adequate vitamin B-12 status by using various
statistical models. Design:We used data on adults ($19 y; n = 12,683) from NHANES 1999–2004—a
nationally representative, cross-sectional survey. We evaluated 6 piece-wise polynomial and exponential decay
models that used different control levels for known covariates. Results: The MMA-defined change point for
SB-12 varied depending on the statistical model used. A linear-splines model was determined to best fit the
data, as determined by the approximate permutation test; 3 slopes relating SB-12 and MMA and resulting in 2
change points and 3 subgroups were shown. The first group (SB-12 ,126 pmol/L) was small and had the
highest MMA concentration (median: 281 nmol/L; 95% CI: 245, 366 nmol/L; n = 157, 1.2%); many in this
group could be considered at high risk of severe deficiency because combined abnormalities of MMA and
homocysteine were very frequent and the concentrations themselves were significantly higher. The highest
SB-12 group (SB-12 .287 pmol/ L; n = 8569, 67.6%) likely had adequate vitamin B-12 status (median MMA:
120 nmol/L; 95% CI: 119, 125 nmol/L). The vitamin B-12 status of the sizable intermediate group (n = 3957,
33%) was difficult to interpret. Conclusions: The 3 distinct slopes for the relation between SB-12 and MMA
challenges the conventional use of one cutoff point for classifying vitamin B-12 status. In epidemiologic
research, the use of one cutoff point would fail to separate the small, severely deficient group from the
intermediate group that has neither normal nor clearly deficient vitamin B-12 concentrations (ie, unknown
vitamin B-12 status). This intermediate group requires further characterization.
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ABSTRACT
Background: No consensus exists about which cutoff point should
be applied for serum vitamin B-12 (SB-12) concentrations to define
vitamin B-12 status in population-based research.
Objective: The study’s aim was to identify whether a change point
exists at which the relation between plasma methylmalonic acid
(MMA) and SB-12 changes slope to differentiate between inade-
quate and adequate vitamin B-12 status by using various statistical
models.
Design:We used data on adults ($19 y; n = 12,683) from NHANES
1999–2004—a nationally representative, cross-sectional survey. We
evaluated 6 piece-wise polynomial and exponential decay models
that used different control levels for known covariates.
Results: The MMA-defined change point for SB-12 varied depend-
ing on the statistical model used. A linear-splines model was de-
termined to best fit the data, as determined by the approximate
permutation test; 3 slopes relating SB-12 and MMA and resulting
in 2 change points and 3 subgroups were shown. The first group
(SB-12 ,126 pmol/L) was small and had the highest MMA con-
centration (median: 281 nmol/L; 95% CI: 245, 366 nmol/L; n = 157,
1.2%); many in this group could be considered at high risk of severe
deficiency because combined abnormalities of MMA and homocys-
teine were very frequent and the concentrations themselves were
significantly higher. The highest SB-12 group (SB-12 .287 pmol/
L; n = 8569, 67.6%) likely had adequate vitamin B-12 status (me-
dian MMA: 120 nmol/L; 95% CI: 119, 125 nmol/L). The vitamin
B-12 status of the sizable intermediate group (n = 3957, 33%) was
difficult to interpret.
Conclusions: The 3 distinct slopes for the relation between SB-12
and MMA challenges the conventional use of one cutoff point for
classifying vitamin B-12 status. In epidemiologic research, the use
of one cutoff point would fail to separate the small, severely de-
ficient group from the intermediate group that has neither normal
nor clearly deficient vitamin B-12 concentrations (ie, unknown vi-
tamin B-12 status). This intermediate group requires further char-
acterization. Am J Clin Nutr 2013;98:460–7.
INTRODUCTION
Serum vitamin B-12 (SB-12)5 concentrations directly reflect
circulating vitamin B-12 concentrations, whereas methyl-
malonic acid (MMA) accumulates in the absence of adequate
vitamin B-12 concentrations and is considered a “functional”
indicator of vitamin B-12 status (1, 2). Each of these biomarkers
has limitations in sensitivity and specificity. To minimize these
limitations, some experts have suggested the use of both a direct
measure and a functional measure to assess vitamin B-12 status
in population-based studies (3–7). Previously, using this com-
bined biomarker approach with commonly used cutoff points for
adults in NHANES, we determined that w1% of US adults had
both a low SB-12 and a high plasma MMA concentration, which
indicated a suboptimal vitamin B-12 status (8).
A critical step in defining a population’s vitamin B-12 status
is the selection of applicable cutoffs (3). Recently, a roundtable
of experts identified uncertainties in the published cutoff points
for biomarkers of vitamin B-12 status (7). Indeed, when this
group applied different cutoff points that are commonly used in
the scientific literature to each biomarker in isolation, the
prevalence of low SB-12 concentrations ranged from 3% to
26%, and the prevalence of high MMA concentrations ranged
from 2% to 6% (8).
The purpose of the current analysis was to examine whether
a change point exists at which the relation between SB-12 and
MMA concentrations changes the slope to help differentiate
between adequate and inadequate vitamin B-12 status (9, 10). We
used various statistical models with data on a large NHANES
population after controlling for confounding variables that are
known to affect these biomarker measurements but are not related
to vitamin B-12 status.
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SUBJECTS AND METHODS
NHANES
NHANES is a nationally representative, cross-sectional survey
of the noninstitutionalized US population that uses a complex,
stratified, multistage probability cluster sampling design. The
National Center for Health Statistics of the CDC collects the
NHANES data. Survey participants are first interviewed in their
homes; at this interview, demographic information, data on di-
etary supplement use, and some health-related data are collected.
Participants then complete a standardized physical examination,
24-h dietary recall, and a blood draw in a mobile examination
center w1–2 wk later.
Analytic sample
For this study, we combined data from NHANES 1999–2000,
2001–2002, and 2003–2004 (n = 31,126). We excluded data on
anyone younger than 19 y (n = 14,942); those with only in-
terview data (ie, lacking mobile examination center data, n =
1160); lactating (n = 145) and pregnant (n = 802) females; and
those with missing MMA (n = 928), SB-12 (n = 114), or cre-
atinine (n = 107) data. We also excluded those with SB-12
concentrations greater than the 99th percentile (.1265 pmol/L;
range: 25–148,935 pmol/L; n = 135). Extraordinarily high SB-
12 concentrations almost always reflect phenomena that are
unrelated to vitamin B-12 metabolism or status and can exert
substantial influence over the change point, leading to biased
models. Finally, we excluded those with an estimated glomer-
ular filtration rate (eGFR) ,30 (n = 116) because impaired
kidney function increases MMA and vitamin B-12 concentra-
tions independently of vitamin B-12 status (see Supplemental
Table 1 under “Supplemental data” in the online issue). The final
analytic sample size was 12,683. Written informed consent was
obtained from all participants; the survey protocol was approved
by the Research Ethics Review Board of the National Center for
Health Statistics. Interview and examination response rates for
each survey year are publicly available (11).
Biochemical methods
NHANES 1999–2004 measured SB-12 concentrations with
the use of the Quantaphase II radioassay (BioRad). Plasma total
homocysteine (tHcy) concentrations were measured by using
a fluorescence polarization immunoassay reagent kit (Abbott
Laboratories) (12) and plasma MMA concentrations by gas
chromatography–mass spectrometry after cyclohexanol de-
rivatization of the extracted MMA. NHANES 1999–2000 mea-
sured serum creatinine by using the Jaffe method with the
Hitachi 917 multichannel analyzer, and NHANES 2001–2004
used the Jaffe rate method (kinetic alkaline picrate) with the
Beckman Synchron LX20 modular chemistry analyzer. We ad-
justed serum creatinine data for NHANES 1999–2000 using the
equation 0.147 + 1.013 3 uncorrected serum creatinine (mg/dL),
as the analytic note recommends (13). High-sensitivity C-reactive
protein was measured by latex-enhanced nephelometry on a BN
II nephelometer (Dade Behring). Details and documentation for
each of these methods and the biomarker coefficients of variations
for each survey year are publicly available on the NHANES
website (14–16).
Vitamin B-12 exposure
Dietary supplement information was collected via the
NHANES Dietary Supplement Questionnaire, which determines
each participant’s intakes of vitamins, minerals, herbs, and other
dietary supplements over the past 30 d. The average daily intake
of vitamin B-12 from all supplements was calculated (17). Six
participants in our sample had very high intakes of supplemental
vitamin B-12; because this might have been a result of the
metric in which the dose was provided (mL), we are uncertain
whether the data on their intake are reliable. We Winsorized
these 6 observations to the next highest value of 3000 mg.
Data on one 24-h dietary recall are available for each par-
ticipant for 1999–2002 and on two 24-h dietary recalls for 2003–
2004. We used the vitamin B-12 intakes from the first 24-h dietary
recall from 2003 to 2004; if day 1 24-h dietary recall data were
missing but day 2 data were available, we used the day 2 data.
We report intake data as means or medians rather than the pre-
valence of low values because of the inability to correct for
within-person variability. Because of limitations in the food-
composition databases, estimates of vitamin B-12 intake in
1999–2004 did not account for bioavailability differences be-
tween naturally occurring and added vitamin B-12 sources (18).
We combined data on the average daily intake of vitamin B-12
from supplemental sources with the daily estimates of vitamin
B-12 intake from foods to reflect total vitamin B-12 exposure.
Dietary data were available for 12,124 participants.
Statistical models and analysis
We estimated descriptive statistics of the sample by using
SAS-Callable Sudaan (version 9.3) and used the examination
survey weights to make the estimates reflective of the US adult
population. We determined statistical comparisons by using
diffvar statements in PROC DESCRIPT. We log transformed any
nonnormal variables before statistical comparison. The median
MMA concentrations, tHcy concentrations, and dietary vitamin
B-12 intakes might be more descriptive of each group than the
mean values, because some very high values skewed the means
and, thus, their interpretability. ORs of having elevated MMA
(.271 nmol/L) or tHcy (.13 nmol/L) were derived via PROC
RLOGIST in Sudaan. Statistical significance was set at P, 0.05
All models
To reduce heteroscedasticity and skewness of the distribution,
we selected the log-transformed MMA concentration as the
dependent variable after examining several possible trans-
formations for both MMA and SB-12. All models were examined
with several covariates that were significant predictors of log-
MMA in stepwise regression models; the covariates that we
examined included eGFR, age, ethnicity, dietary and supple-
mental intakes of vitamin B-12, use of antibiotics, session of
blood collection, hours of fasting, and C-reactive protein con-
centrations. We examined all models using 3 tiers of adjustment.
Tier 1 was unadjusted, tier 2 was minimally adjusted (ie, for
eGFR, hours of fasting before the blood draw, and age), and tier 3
was maximally adjusted (ie, for all covariates). We found no
appreciable differences in the models based on the tier level of
adjustment that we used. We therefore present results using the
minimally adjusted models, which controlled only for the most
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relevant factors. Use of these models maximized the df and
therefore enhanced statistical reliability while ensuring that
adjustments for the effects of known biological covariates were
made.
The first step was to use locally weighted regression or the
locally estimated scatterplot smoothing (LOESS) technique.
LOESS is an unweighted nonparametric scatterplot of the data to
define the optimal shape of the function to summarize the nature
of the relation for the 2 biomarkers (19, 20). Once confirmed by
the LOESSmodel, we used 2 broad types of modeling procedures
(exponential decay and piece-wise polynomial) to best “mimic”
the shape of the function of the relation of SB-12 and log-MMA
concentrations. For both of these model types, we accounted for
the multistage sampling scheme and sampling weights by using
an adaptation of the SVY module in the STATA statistical
package (version 12; StataCorp). The change point estimates
were first determined for each model type; the 95% CIs around
the change point estimates were derived by a bootstrapping tech-
nique that accounted for the survey design. The bootstrap method
for complex survey data are implemented by the bsweights
command in STATA (21).
Exponential model
Exponential models, sometimes called nonlinear exponential
or exponential decay models, are ideal for working with bi-
ological phenomena because they permit modeling of the non-
linear relation between 2 variables and estimations of the rate of
change of one variable (y) as a function of another (x) while
confounding factors are accounted for. Specifically, the follow-
ing model was fit to our data:
logðMMAÞ ¼ AþB3 e2 c3B12 ð1Þ
where A, B, and C are nonnegative variables to be estimated.
Notice that this exponential curve approaches a plateau equal to
the variable A for large values of vitamin B-12. Thus, for the
exponential model in this analysis, the “no change” point was
defined as the smallest value of SB-12 for which log-MMA is
not significantly different from its plateau value under the
model. Precisely, the variable A was estimated along with the
corresponding SE by using the least-squares method. The point
of “no-change” was determined as that value of vitamin B-12 for
which log MMA, under the model, equals the upper limit of the
95% CI of A. CIs for the “no change” point were calculated by
the bias corrected bootstrap approach, accounting for design
effects.
Piece-wise polynomial
In the linear-linear model, 2 lines are fit to the data; these 2
lines are connected at the change point or “knot.” We applied 2
additional piece-wise polynomial models to the data. The other
“2-phase” models (ie, linear-quadratic and quadratic-quadratic)
did not improve the fit compared with the simpler linear-linear
model, and we do not discuss them extensively in this report.
The linear-splines model draws several smaller lines throughout
the data, and these lines are joined in an iterative process to
reduce the residual sum of squares; these minimal join points
were used to determine the change point for the linear-splines
model. The 2-knot approach that we used in this analysis had 3
phases: during phase 1, MMA concentrations declined rapidly
with increasing SB-12 concentrations; in phase 2, MMA con-
centrations decreased much more slowly with increasing SB-12
concentrations; and in phase 3, MMA concentrations no longer
changed as a function of SB-12 concentrations.
For all of the piece-wise models, we estimated the regression
parameters and change points by performing a grid search (22).
Briefly, we divided the vitamin B-12 distribution range into an
equally spaced grid. For the one-knot (linear-linear) model, we
fitted a piece-wise linear model for each of the grid values. We
deemed the grid values resulting in the smallest residual sum of
squares to be the best estimator of the change point. We esti-
mated the 2 change points in a 2-knot model in a similar fashion
by selecting 2 grid values at a time and fitting a piece-wise linear
regression model. The model with the smallest residual sum of
squares yielded estimators for the knots and regression param-
eters. Estimation of change points via the grid process makes
use of the residual sum of squares, which in turn uses the
sampling weights information but does not use the survey design
(ie, primary sampling units and strata) in the estimation. The
computer implementation of the grid algorithm requires the
specification of the search range. In this analysis, the data were
examined for the change point between the 1st and 99th per-
centiles of the vitamin B-12 distribution.
Model fit
To determine the most robust of “best-fit” model, we tested
the selection between the zero-knot (linear regression), one-
knot (linear-linear), and 2-knot (linear-splines) models using an
TABLE 1
Change points derived for serum vitamin B-12 as a function of plasma
MMA by using different modeling techniques1
Change points (95% CIs) R2 value2
pmol/L %
Exponential 212 (184, 289) 24.7
Linear-linear 193 (182, 279) 24.0
Linear-quadratic 260 (192, 371) 22.8
Quadratic-quadratic 314 (266, 442) 23.7
Linear splines3 126 (117, 182), 287 (253, 434) 25.1
1Data from NHANES 1999–2000, 2001–2002, and 2003–2004
(n = 31,126) were combined. Data for participants younger than 19 y
(n = 14,942); those with only interview data (n = 1160); lactating (n = 145) and
pregnant (n = 802) females; those with missing data on MMA (n = 928),
serum vitamin B-12 (n = 114), or creatinine (n = 107) concentrations; those
with a serum vitamin B-12 concentration greater than the 99th percentile
(.1265 pmol/L; n = 135); and those with a glomerular filtration rate ,30
(n = 110) were excluded. The final analytic sample size was 12,683. Age,
glomerular filtration rate, and hours of fasting were controlled for before the
blood samples were drawn. Other relevant covariates were examined, which
were not influential in determining the change point. See supplementary
analytic materials under “Supplemental data” in the online issue for details.
NHANES assessed serum vitamin B-12 concentrations by using the Quan-
taphase II radioassay from BioRad and plasma MMA concentrations with
gas chromatography–mass spectrometry. MMA, methylmalonic acid.
2Defined as the amount of variability in serum vitamin B-12 that is
explained by the model; this value is not interpreted as a fit statistic.
3The linear-splines (2-knot) model was statistically more robust than
was the exponential model (ie, zero-knot; P , 0.001) or the one-knot model
(P , 0.001), determined by the approximate permutations test.
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approximate permutation test to determine the best model to
describe the relation between SB-12 and log-MMA (23). This
procedure was used to test whether the 2-knot model is preferred
over the zero-knot model. If significant, then compare the 2-knot
compared with the one-knot model. The first step in the appli-
cation of the approximate permutation test is to fit the null
model (ie, the zero-knot model) and compute the residuals
(observed minus expected), followed by randomly permutating
these residuals and adding them to predicted value (under the
null model). Next, a grid search approach is applied to fit the
alternative model (ie, 2-knot model) to the resulting data and
compute the residuals. An F-like goodness-of-fit test statistic is
constructed by using these 2 sets of residuals. The distribution of
this test statistic is approximated by Monte Carlo simulations,
and P values are determined from the resulting distribution.
RESULTS
We determined different SB-12 change points by using each
model strategy (Table 1). The exponential model with its cur-
vilinear rate of change most closely mimicked the LOESS curve
(ie, the curve that describes the scatter of the 2 variables)
(Figure 1). Using the LOESS procedure by age group, we ob-
served a similarly shaped curve in the relation between MMA
and SB-12 concentrations across age groups, although the curves
occurred at higher MMA values for groups with increasing age
(Figure 2).
The statistically based approximate permutation test showed
that the linear-splines model best fit the data to describe the
relation between SB-12 and MMA concentrations better than the
exponential model (P , 0.001) or any of the “one-knot” models
(P , 0.001) (see Supplemental Figures 1 and 2 under “Sup-
plemental data” in the online issue). The slope of the relation
between MMA and SB-12 concentrations was significantly
different for each of the groups that we created by the linear-
splines model (Figure 3; see Supplemental Table 2 under
“Supplemental data” in the online issue). By using the cutoff
points that we derived from the linear-splines model for SB-12
concentrations (Table 1), we examined 3 groups of adults by
serum vitamin B-12 concentration: group 1, ,126; group 2,
126–287, and group 3, .287 pmol/L (Table 2). Group 1 had a
high risk of vitamin B-12 deficiency and represented a very
small proportion of adults in the United States. In addition,
group 1 had the highest MMA and tHcy concentrations. The
group with the highest SB-12 concentrations, group 3, had the
lowest MMA and tHcy concentrations. NHANES participants in
the middle group (126–287 pmol/L), group 2, had intermediate
median MMA (148 nmol/L) and tHcy (9 mmol/L) concentra-
tions, although their values for these 2 biomarkers were closer to
those of the highest SB-12 group (120 nmol/L and 8 mmol/L,
respectively) than to those of the lowest SB-12 group (281 nmol/
L and 12 mmol/L, respectively). When compared with group 3,
both group 1 and group 2 had a significantly increased odds of
having an elevated MMA or tHcy concentration: group 1 com-
pared with group 3 [MMA OR: 32.1 (95% CI: 21.6, 47.8);
tHcy OR: 18.5 (95% CI: 13.9, 24.5)], group 2 compared with
group 3 [MMA OR: 3.5 (95% CI: 2.9, 4.3); tHcy OR: 3.1 (95%
CI: 2.7, 3.6)]. We observed no differences between the groups in
FIGURE 1. LOESS, exponential, linear-linear, and linear-splines models
of the relation between serum vitamin B-12 and log-MMA concentrations
among US adults aged $19 y, 1999–2004. Data from NHANES 1999–
2000, 2001–2002, and 2003–2004 (n = 31,126) were combined. Data for
participants younger than 19 y (n = 14,942); those with only interview data
(n = 1160); lactating (n = 145) and pregnant (n = 802) females; those with
missing data on MMA (n = 928), serum vitamin B-12 (n = 114), or creatinine
(n = 107) concentrations; those with a serum vitamin B-12 concentration
greater than the 99th percentile (.1265 pmol/L; n = 135); and those with a
glomerular filtration rate ,30 (n = 110) were excluded. The final analytic
sample size was 12,683. Age, glomerular filtration rate, and hours of fasting
were controlled for before the blood samples were drawn. Other relevant
covariates were examined, which were not influential in determining the
change point. See supplementary analytic materials under “Supplemental
data” in the online issue for details. NHANES assessed serum vitamin B-12
concentrations by using the Quantaphase II radioassay from BioRad and
plasma MMA concentrations with gas chromatography–mass spectrometry.
LOESS, locally estimated scatterplot smoothing; MMA, methylmalonic acid.
FIGURE 2. LOESS of the relation between serum vitamin B-12 and log-
MMA concentrations by 10-y age groupings among US adults, 1999–2004.
Data from NHANES 1999–2000, 2001–2002, and 2003–2004 (n = 31,126)
were combined. Data for participants younger than 19 y (n = 14,942); those
with only interview data (n = 1160); lactating (n = 145) and pregnant (n =
802) females; those with missing data on MMA (n = 928), serum vitamin
B-12 (n = 114), or creatinine (n = 107) concentrations; those with a serum
vitamin B-12 concentration greater than the 99th percentile (.1265 pmol/L;
n = 135); and those with a glomerular filtration rate ,30 (n = 110) were
excluded. The final analytic sample size was 12,683. Age, glomerular filtration
rate, and hours of fasting were controlled for before the blood samples were
drawn. Other relevant covariates were examined, which were not influential
in determining the change point. See supplementary analytic materials under
“Supplemental data” in the online issue for details. NHANES assessed serum
vitamin B-12 concentrations by using the Quantaphase II radioassay from
BioRad and plasma MMA concentrations with gas chromatography–mass
spectrometry. LOESS, locally estimated scatterplot smoothing; MMA,
methylmalonic acid.
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creatinine, eGFR, or C-reactive protein concentrations (data not
shown).
Group 1 members tended to be older, and female members of
group 3 were more likely to be non-Hispanic black or Mexican
American. Group 2 is a group of people whose age and sex
profiles were significantly different from those of both the lowest
and highest SB-12 groups and more closely resembled those of
group 3. Racial-ethnic characteristics did not differ significantly
between groups 2 and 1; however, the highest proportion of non-
Hispanic whites was in group 1, and the highest proportion of
non-Hispanic blacks was in group 3.
We observed no differences between the 3 SB-12 groups in
vitamin B-12 intakes from foods alone, and the intakes from food
sources appeared to be adequate with mean and median intakes
above the Estimated Average Requirements of 2.0 mg/d (18).
However, intakes from dietary supplements differed signifi-
cantly, ranging from a mean (6SE) of 10.3 6 1.5 mg/d in the
group 1 to 75.4 6 13.1 mg/d in group 3. Thus, differences in
total intakes between groups were due almost exclusively to
differences in supplement use.
DISCUSSION
With the use of various statistical models, we quantified the
complex relation between SB-12 and plasma MMA concentra-
tions. The best-fit model produced 3 different and independent
slopes for the relation between SB-12 and MMA concentrations
and yielded 2 points of change. This strategy thereby identified 3
subsets of the adult US population along the continuum of vi-
tamin B-12 status that has been previously described by others in
the field (4–7). However, our work is the first to use a statistical
model that specifically identifies an intermediate group of peo-
ple based on 2 cutoff points. Previous epidemiologic researchers
would have classified these people as having either deficient or
sufficient vitamin B-12 status, but neither of these classifications
seem appropriate for this group.
FIGURE 3. The linear-splines model of the relation between serum vitamin B-12 and log-MMA concentrations among US adults, 1999–2004. Data from
NHANES 1999–2000, 2001–2002, and 2003–2004 (n = 31,126) were combined. Data for participants younger than 19 y (n = 14,942); those with only
interview data (n = 1160); lactating (n = 145) and pregnant (n = 802) females; those with missing data on MMA (n = 928), serum vitamin B-12 (n = 114), or
creatinine (n = 107) concentrations; those with a serum vitamin B-12 concentration greater than the 99th percentile (.1265 pmol/L; n = 135); and those with
a glomerular filtration rate ,30 (n = 110) were excluded. The final analytic sample size was 12,683. Age, glomerular filtration rate, and hours of fasting were
controlled for before the blood samples were drawn. Other relevant covariates were examined, which were not influential in determining the change point. See
supplementary analytic materials under “Supplemental data” in the online issue for details. NHANES assessed serum vitamin B-12 concentrations by using
the Quantaphase II radioassay from BioRad and plasma MMA concentrations with gas chromatography–mass spectrometry. A: The shape of the linear-splines
model for NHANES participants with a serum vitamin B-12 concentration ,126 pmol/L. B: Data points for participants with a serum B-12 concentration of
126–287 pmol/L. C: Data points for participants with a serum vitamin B-12 concentration .287 pmol/L. D: The overall shape of the linear-splines model for
all data points. MMA, methylmalonic acid.
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Group 1 was small (representing w1% of US adults) but in-
cluded several individuals with severe vitamin B-12 deficiency
and the highest MMA and tHcy concentrations of any of the 3
groups we identified. Their downward slope between MMA and
SB-12 concentrations was steep across a fairly narrow range of
SB-12 concentrations. Group 3 (w68% of US adults) had opti-
mal vitamin B-12 status and this group had almost a flat tra-
jectory for the relation between vitamin B-12 and MMA
concentrations across a very wide range of SB-12 values (Figure
3C). Group 2, the remaining third (31%) of US adults, had SB-12
concentrations between the 2 change points. The members of
group 2 had a vitamin B-12 status that is arguably much more
difficult to interpret than the status of the other 2 groups. The
increase in MMA in group 2 for a given SB-12 value was smaller
than that of group 1 and larger than that of group 3 (Figure 3C).
The median MMA and tHcy concentrations of group 2 were not
much higher than those of group 3, but the odds of having ele-
vations in these functional indicators was 3-fold [MMA OR: 3.5
(95% CI: 2.9, 4.3); tHcy OR: 3.1 (95% CI: 2.7, 3.6)].
The demographic data gave a mixed picture of group 2, the age
and sex profiles of which were similar to those of group 3 and
whose racial-ethnic profiles were similar to those of group 1. It is
unknown to what extent individuals in this middle group were
likely to progress to the more obvious vitamin B-12 deficiency in
group 1, which individuals were simply experiencing a mild or
temporary period of vitamin B-12 deficiency, and which in-
dividuals had reduced SB-12 for reasons unrelated to vitamin
B-12 deficiency [eg, polymorphisms within the FUT2 gene and
mutations within the TCN1 gene that alter SB-12 without al-
tering MMA or tHcy concentrations (24, 25)]. Previous studies
have found elevated concentrations of functional biomarkers
(MMA and/or tHcy) in cases in which SB-12 concentrations
were within the normal range (3, 9, 26). Although several ob-
servational studies have suggested that vitamin B-12 concen-
trations in the low-normal range are associated with cognitive
function or decline and impaired nervous system function (as
reviewed in reference 10), these results require confirmation in
clinical trials (7).
The second unique finding of this study was that, although
each of the models produced the expected curvilinear relation
between MMA and SB-12 concentrations, each model also
produced different points of change for SB-12 concentrations.
TABLE 2
Demographic, biochemical, and dietary variables by change points determined with the linear-splines approach among US
adults, 1999–20041
Serum vitamin B-12 concentrations
,126 pmol/L
(n = 157)
126–287 pmol/L
(n = 3957)
.287 pmol/L
(n = 8569)
Percentage of sample (%) 1 33 66
Demographic characteristics2
Age (y) 53 6 1a,3 45 6 0.3b 46 6 0.3c
$60 y (%) 37 6 4a 21 6 1b 23 6 1c
Male (%) 37 6 5a 48 6 1b 51 6 1c
Non-Hispanic white (%) 81 6 4a 76 6 2a 70 6 2b
Non-Hispanic black (%) 6 6 2a 7 6 1a 12 6 1b
Mexican American (%) 5 6 1a 6 6 1a 8 6 1b
Biochemical variables4
Plasma MMA (nmol/L) 719 6 113a 176 6 2b 137 6 2c
Median (nmol/L) 281 (245, 366) 148 (140, 153) 120 (119, 125)
Plasma tHcy (mmol/L) 17 6 2a 10 6 0.1b 8 6 0.1c
Median (mmol/L) 12 (10.9, 13.1) 9 (8.5, 8.8) 8 (7.6, 7.8)
Dietary components
Vitamin B-12 from food sources (mg/d) 4.7 6 0.5 4.7 6 0.2 5.5 6 0.1
Median (mg/d) 3.1 (2.5, 3.6) 3.4 (3.3, 3.6) 4.1 (3.9, 4.3)
Vitamin B-12 from dietary supplements (mg/d)5 10.3 6 1.5a 38.8 6 9.1b 75.4 6 13.1c
Median (mg/d) 5.9 (5.6, 8.0) 6.0 (5.9, 6.0) 9.9 (8.8, 11.8)
Percentage using vitamin B-12 supplements (%) 24 6 4a 24 6 1a 45 6 1b
Total vitamin B-12 intake (mg/d) 7.2 6 0.7a 14.4 6 2.3b 39.6 6 6.2c
Median (mg/d) 3.7 (3.3, 5.9) 4.5 (4.3, 4.8) 7.7 (7.6, 7.8)
1Data from NHANES 1999–2000, 2001–2002, and 2003–2004 (n = 31,126) were combined. Data for participants
younger than 19 y (n = 14,942); those with only interview data (n = 1160); lactating (n = 145) and pregnant (n = 802)
females; those with missing data on MMA (n = 928), serum vitamin B-12 (n = 114), or creatinine (n = 107) concentrations;
those with a serum vitamin B-12 concentration greater than the 99th percentile (.1265 pmol/L; n = 135); and those with
a glomerular filtration rate ,30 (n = 110) were excluded. The final analytic sample size was 12,683. 95% CIs in
parentheses. Values in a row with different superscript letters are significantly different, P # 0.05 [determined by a diffvar
statement in PROC DESCIPT (SAS-callable Sudann)]. MMA, methylmalonic acid; tHcy, total homocysteine.
2 Percentages do not add up to 100 because data for the “other” racial-ethnic group are not presented.
3Mean 6 SE (all such values).
4NHANES assessed serum vitamin B-12 concentrations by using the Quantaphase II radioassay from BioRad, plasma
MMA concentrations by using gas chromatography–mass spectrometry, and plasma homocysteine concentrations by using
a fluorescence polarization immunoassay reagent kit from Abbott Laboratories.
5Estimates are for users of dietary supplements only; the total is for users and nonusers of supplements combined.
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Thus, the derived change point is model dependent. This finding
could explain some of the differences in change point con-
centrations between published studies whose authors relied
primarily on a single statistical model approach without ex-
plaining why they chose the model they used (9, 27). For ex-
ample, Vogiatzoglou et al (27) used a segmented linear regression
to identify a change point of 334 pmol/L for SB-12 as a function
of MMA concentration in the Hordaland Homocysteine Study in
Norway; because the authors did not specify how many linear
segments they used in this study, a comparison of data from this
study to our data are not possible. Conversely, the differences
in change point are smaller in our study than in the results of
Selhub et al (9), who used a linear-linear model that is similar to
one of the models we tested (Table 1). Selhub et al found a
change point of 150 pmol/L in an NHANES III sample, whereas
we found a change point of 194 pmol/L using the same model
in an NHANES 1999–2004 sample. Because of differences
in the survey years, the ages of the subjects, changes in
MMA assay methods, and use of different exclusion criteria
and covariates, a more thorough comparison of these 2 studies
cannot be achieved. Our linear-splines model suggested that
using only one cutoff point to define status in survey data
often leads to inappropriately dividing members of the in-
termediate group into sufficient and deficient groups. Fur-
thermore, the use of traditional groupings (eg, quartiles or
centiles) in epidemiologic research often hides the small, but
clearly deficient, group by combining its members with per-
sons in the more “intermediate” group. Both of these practices
led to misclassification.
The 3-phase approach that we used is appealing not only
because of its superior ability to identify subgroups but also
because of its biological plausibility. The underlying patho-
physiologic causes and known health risks in the deficient and
intermediate groups might have been different (3). The utility of
the linear-splines framework to understand vitamin B-12 status
needs to be confirmed in other population-based surveys and is
probably not practical for clinical applications in which a single
cutoff point is used.
This analysis had some limitations. Age affected the relation
between MMA and SB-12 concentrations in our analyses. The
NHANES data were cross-sectional, and the survey assessed the
relations between SB-12 and MMA concentrations at a single
point in time. We examined several but not all types of statistical
models. Because the major determinants of MMA are largely
unknown (27), we probably missed some key covariates. Finally,
the gold-standard approach for identifying cutoff points is the
randomized clinical trial or repletion study. No data from such
studies are currently available, and the statistical approach that
we used is at best an interim approach pending the availability of
such data. A common problem in understanding vitamin B-12
status in any population is that both SB-12 and MMA concen-
trations vary by age independently of vitamin B-12 status (9, 22).
For this reason, we recognized that the cutoff points that we
derived might not be optimal for different age subgroups or
populations (3).
Given the negative cognitive and other health consequences
that can result from clinical vitamin B-12 deficiency, it is critical
to accurately monitor the vitamin B-12 status among all age
groups, especially among the oldest groups. This study highlights
the difficulty (in the absence of clinical trials) of defining the
vitamin B-12 status of the population and underscores the un-
certainty regarding interpretations of the available data from
NHANES to estimate the population prevalence of vitamin B-12
deficiency. These data also show the need for caution when
selecting a statistical modeling approach to derive cutoff points.
Epidemiologic applications will benefit from the recognition of
the variability among statistical models and the need to critically
evaluate how best to integrate statistical, biological, and practical
considerations when selecting change points for assessing vita-
min B-12 status.
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